Completed PHASE2 INTERVENTIONAL 2-arm NCT02079766

18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy

18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects With Repetitive Brain Trauma at High Risk for Chronic Traumatic Encephalopathy

Sponsor: Avid Radiopharmaceuticals

Conditions Chronic Traumatic Encephalopathy

Interventions Flortaucipir F18 florbetapir F 18

Updated 9 times since 2017 Last updated: Sep 3, 2020 Started: Jun 30, 2014 Primary completion: Oct 31, 2015 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Chronic Traumatic Encephalopathy, this trial is completed. The trial is conducted by Avid Radiopharmaceuticals and has accumulated 9 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Mar 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2022 — Mar 2022 [monthly]

Completed PHASE2
Jan 2021 — Jan 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Oct 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Oct 2020 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Avid Radiopharmaceuticals

Data source: Avid Radiopharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States
• Phoenix, United States